This is a Validated Antibody Database (VAD) review about rhesus mac.. FOXP3, based on 167 published articles (read how Labome selects the articles), using FOXP3 antibody in all methods. It is aimed to help Labome visitors find the most suited FOXP3 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Invitrogen
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...; fig 6c
Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples (fig 6c). Cell Death Dis (2020) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig s6a
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig s6a). J Clin Invest (2020) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...; fig 2a
Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples (fig 2a). Arthritis Res Ther (2020) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; human; 1:100; loading ...; fig 2b
Invitrogen FOXP3 antibody (eBioscience, 14-4777) was used in immunohistochemistry on human samples at 1:100 (fig 2b). Cancer Immunol Immunother (2020) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 1a
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 1a). Front Immunol (2019) ncbi
mouse monoclonal (236a/E7)
  • mass cytometry; human; loading ...; fig 2b
Invitrogen FOXP3 antibody (ThermoFisher, 14-4777-82) was used in mass cytometry on human samples (fig 2b). Cell (2019) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...; fig s7a
Invitrogen FOXP3 antibody (Thermo Fisher, 25-4777-41) was used in flow cytometry on human samples (fig s7a). Cell (2019) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; mouse; loading ...; fig s7c
Invitrogen FOXP3 antibody (Invitrogen, 11-4777-42) was used in flow cytometry on mouse samples (fig s7c). Cell Metab (2019) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...; fig 1a
Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples (fig 1a). Proc Natl Acad Sci U S A (2019) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 2a
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 2a). Cancer (2019) ncbi
rat monoclonal (PCH101)
  • immunohistochemistry - frozen section; human; loading ...; fig 2c
Invitrogen FOXP3 antibody (eBiosciences, PCH101) was used in immunohistochemistry - frozen section on human samples (fig 2c). J Infect Dis (2018) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - frozen section; human; fig 1a
Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in immunohistochemistry - frozen section on human samples (fig 1a). J Exp Med (2018) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; mouse; fig s2b
Invitrogen FOXP3 antibody (eBioscience, 12-4777-42) was used in flow cytometry on mouse samples (fig s2b). Cell (2018) ncbi
rat monoclonal (PCH101)
  • flow cytometry; mouse; loading ...; fig 7a
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on mouse samples (fig 7a). J Clin Invest (2018) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; 1:100; fig 1a
Invitrogen FOXP3 antibody (eBioscience, 12-4776-42) was used in flow cytometry on human samples at 1:100 (fig 1a). Nat Commun (2018) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 5a
Invitrogen FOXP3 antibody (ebioscience, PCH101) was used in flow cytometry on human samples (fig 5a). Sci Rep (2017) ncbi
rat monoclonal (PCH101)
  • mass cytometry; human; loading ...; fig 2a
In order to investigate the immune composition of tumor microenvironment in hepatocellular carcinoma, Invitrogen FOXP3 antibody (eBiosciences, PCH101) was used in mass cytometry on human samples (fig 2a). Proc Natl Acad Sci U S A (2017) ncbi
rat monoclonal (PCH101)
  • immunohistochemistry; human; loading ...; fig 8a
In order to investigate the tumor microenvironment in tertiary lymphoid organs of prostate cancer patients, Invitrogen FOXP3 antibody (ebioscience, PCH101) was used in immunohistochemistry on human samples (fig 8a). Front Immunol (2017) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 1f
In order to study the oncogenic role of ERK1 in glioma, Invitrogen FOXP3 antibody (ebioscience, 12-4776) was used in flow cytometry on human samples (fig 1f). J Immunol (2017) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...
In order to find that oral administration of a selective Rho-associated kinase 2 inhibitor, KD025, reduces psoriasis area in 46% of patients with psoriasis vulgaris, Invitrogen FOXP3 antibody (eBioscience, 25-4777) was used in flow cytometry on human samples . J Immunol (2017) ncbi
rat monoclonal (PCH101)
  • western blot; human; fig 2g
In order to examine the effect of glucose-6-phosphate transporter mutation on immune cell homeostasis and CD4+ T cell functions, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in western blot on human samples (fig 2g). J Immunol (2017) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 6f
In order to investigate origin of tumor-infiltrating T regulatory cells in breast cancer samples, Invitrogen FOXP3 antibody (Thermo Fisher Scientific, 12-4776) was used in flow cytometry on human samples (fig 6f). Cell Res (2017) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...; fig 3a
In order to investigate origin of tumor-infiltrating T regulatory cells in breast cancer samples, Invitrogen FOXP3 antibody (Thermo Fisher Scientific, 17-4777) was used in flow cytometry on human samples (fig 3a). Cell Res (2017) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...; fig 3b
Invitrogen FOXP3 antibody (eBiosciences, 236A/E7) was used in flow cytometry on human samples (fig 3b). J Immunol (2017) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 2
In order to examine the potential of IL-2 to enhance T regulatory cell therapy, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 2). Clin Exp Immunol (2017) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 3b
In order to characterize the periferal blood lymphocytes phenotype in tacrolimus-treated liver transplanted patients., Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 3b). Med Princ Pract (2017) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 2e
In order to observe that the use of chimeric antigen receptor technology is a clinically applicable refinement of regulatory T cell therapy for organ transplantation, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 2e). Am J Transplant (2017) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...; fig 1a
In order to develop a method to assess the capacity of human regulatory T cells to suppress IgM production from an immature human B cell line, Invitrogen FOXP3 antibody (eBioscience, 48-4777-42) was used in flow cytometry on human samples (fig 1a). J Immunol Methods (2017) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; loading ...; fig 6
  • flow cytometry; human; loading ...; fig 1a
In order to establish the T Cell receptor-inducible costimulator as a promising target for direct T regulatory cell-targeting therapeutic agents for gastric cancer, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in immunohistochemistry - paraffin section on human samples (fig 6) and in flow cytometry on human samples (fig 1a). Int J Cancer (2017) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
  • immunocytochemistry; human; loading ...; fig 4b
Invitrogen FOXP3 antibody (eBiosciences, PCH101) was used in flow cytometry on human samples and in immunocytochemistry on human samples (fig 4b). J Exp Med (2016) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...
In order to assess how ABCG1 loss in T cells affects atherosclerosis, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . J Clin Invest (2016) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 4b
In order to report that patients with PTEN mutations experience autoimmunity and lymphoid hyperplasia, Invitrogen FOXP3 antibody (NatuTec, PCH101) was used in flow cytometry on human samples (fig 4b). J Allergy Clin Immunol (2017) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; 1:100; fig 2
Invitrogen FOXP3 antibody (eBioscience, 14-4777-82) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 2). J Transl Med (2016) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; human; 1:150; fig st1
In order to study the prognostic value of the ratio of CD8 to Treg tumor-infiltrating lymphocyte in bladder cancer, Invitrogen FOXP3 antibody (ebioscience, 14-4777) was used in immunohistochemistry on human samples at 1:150 (fig st1). Oncoimmunology (2016) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig s1
In order to show that ATG16L1 and NOD2 are required for Bacteroides fragilis-mediated protection from colitis, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig s1). Science (2016) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...
In order to study the role of T regulatory cells in patients with immune thrombocytopenic purpura, Invitrogen FOXP3 antibody (eBioscience, 12-4776) was used in flow cytometry on human samples . Turk J Haematol (2016) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...
In order to test if the two hematopoietic systems in patients with mixed chimerism remain functional and study immunological differences, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples . PLoS ONE (2016) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; 1:20; tbl 2
Invitrogen FOXP3 antibody (eBioscience, 12-4776-42) was used in flow cytometry on human samples at 1:20 (tbl 2). Oncoimmunology (2016) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...; fig 1a
In order to explore the role of the JAK/STAT pathway in controlling Foxp3 in regulatory T cells, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples (fig 1a). PLoS ONE (2016) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...; fig 2c
In order to study the pharmacologic inhibition of PI3K and MEK pathways in mixed cultures of human mononuclear cells., Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples (fig 2c). Am J Transplant (2016) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; fig 4
In order to develop an HLA-A2-specific chimeric antigen receptor and use it to generate alloantigen-specific human T regulatory cells, Invitrogen FOXP3 antibody (eBiosciences, 12-4777-42) was used in flow cytometry on human samples (fig 4). J Clin Invest (2016) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 3c
In order to assess the impact of neoantigen intratumor heterogeneity on antitumor immunity, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 3c). Science (2016) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
Invitrogen FOXP3 antibody (eBioscience, 12-4776) was used in flow cytometry on human samples . Immunity (2016) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 1a
In order to examine the relationship between prolactin and T regulatory cells in patients with systemic lupus erythematosus, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 1a). Medicine (Baltimore) (2016) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 8a
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 8a). PLoS Pathog (2016) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 4d
In order to study the role of human head and neck squamous cell carcinoma-associated semaphorin 4d in myeloid-derived suppressor cells, Invitrogen FOXP3 antibody (eBioscience, 12-4776-42) was used in flow cytometry on human samples (fig 4d). J Immunol (2016) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; loading ...; fig 3a
In order to demonstrate that TGF-beta induces the differentiation of human CXCL13-producing CD4 positive T cells from naive CD4 positive T cells, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples (fig 3a). Eur J Immunol (2016) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; rhesus macaque; loading ...; fig 5
In order to describe a selective CD28 antagonist for treatment of rheumatoid arthritis, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on rhesus macaque samples (fig 5). Clin Exp Immunol (2016) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human
In order to study hepatocellular carcinoma and ectopic lymphoid structures function as microniches for tumor progenitor cells, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in immunohistochemistry - paraffin section on human samples . Nat Immunol (2015) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - frozen section; human; 1:100; fig 1
Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in immunohistochemistry - frozen section on human samples at 1:100 (fig 1). Nat Commun (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 4
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 4). Haematologica (2016) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human; 1:100; fig 1
In order to elucidate the prognosis of gastric cancer by tumor-infiltrating immune cells, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 1). Medicine (Baltimore) (2015) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; fig 8
Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples (fig 8). J Clin Invest (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
In order to determine the proportions, phenotype, survival, and apoptotic susceptibility of Tregs in sarcoidosis, Invitrogen FOXP3 antibody (eBiosciences, PCH101) was used in flow cytometry on human samples . Respir Res (2015) ncbi
mouse monoclonal (236a/E7)
  • immunocytochemistry; pigs
  • immunohistochemistry; pigs ; 1:50
In order to discuss the role of nucleocapsid-induced IL-10 production and generation of PRRSV-specific Tregs, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in immunocytochemistry on pigs samples and in immunohistochemistry on pigs samples at 1:50. Vaccine (2015) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human
In order to elucidate the role of IL-10 in human papillomavirus infection, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in immunohistochemistry - paraffin section on human samples . Immunology (2015) ncbi
rat monoclonal (PCH101)
  • immunohistochemistry; human
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in immunohistochemistry on human samples . World J Urol (2016) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
In order to investigate the primary inflammatory and regulatory T cell responses induced by BCG vaccination in adults, Invitrogen FOXP3 antibody (eBioscience, clone PCH101) was used in flow cytometry on human samples . Clin Vaccine Immunol (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 2b
In order to elucidate Th17 cell polarization, depletion, and restoration in response to HIV infection and antiretroviral therapy, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 2b). Retrovirology (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig st1
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig st1). Infect Immun (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; 1 ul/test
In order to analyze mucosal pinch biopsies collected predominantly during colonoscopies, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples at 1 ul/test. J Immunol Methods (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 6
In order to describe the phenotype and functional potential of metastatic differentiated thyroid cancer-associated PD-1 positive T cells, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 6). Cancer Immunol Res (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 2
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 2). Cell Res (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 4
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 4). Nat Immunol (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 2
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 2). Mol Med Rep (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
Invitrogen FOXP3 antibody (eBiosciences, PCH101) was used in flow cytometry on human samples . J Neuroimmunol (2014) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human
Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples . Hum Immunol (2014) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . Hum Immunol (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . J Immunol (2015) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human
Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples . J Immunol (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
Invitrogen FOXP3 antibody (e-Bioscience, PCH101) was used in flow cytometry on human samples . Nat Commun (2014) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
In order to examine the role of TLR7 in HIV-infected CD4 positive T cells, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . Nat Immunol (2015) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human
Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples . PLoS ONE (2014) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 5
In order to study the immune effects of tadalafil in patients with head and neck squamous cell carcinoma., Invitrogen FOXP3 antibody (e-Bioscience, PCH101) was used in flow cytometry on human samples (fig 5). Clin Cancer Res (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . J Immunol (2014) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human
Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples . J Immunol (2014) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - paraffin section; human
Invitrogen FOXP3 antibody (eBioscience, 14-4777-82) was used in immunohistochemistry - paraffin section on human samples . J Immunol (2014) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 3a
In order to show that latency-associated peptide and glycoprotein A repetitions predominant identify human antigen-specific T regulatory cells, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 3a). Eur J Immunol (2014) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 1
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 1). Immunology (2015) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . PLoS ONE (2014) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
In order to determine the presence, frequency, association to other immune parameters, and functional properties of circulating CD14(+) cells lacking HLA-DR expression in patients with untreated chronic lymphocytic leukemia, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . Blood (2014) ncbi
rat monoclonal (PCH101)
  • immunocytochemistry; human
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in immunocytochemistry on human samples . Eur J Immunol (2014) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human
In order to characterize preterm infants and alterations found in regulatory T cell subpopulations, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples . PLoS ONE (2014) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
  • immunocytochemistry; human
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples and in immunocytochemistry on human samples . Mol Oncol (2014) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human
Invitrogen FOXP3 antibody (eBioscience, clone 236A/E7) was used in flow cytometry on human samples . Mol Ther (2014) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human
In order to examine human differentiated effector CD4(+) T cells that are defined by low levels of IL-2 and IL-7 receptors, Invitrogen FOXP3 antibody (eBioscience, 236-A/E7) was used in flow cytometry on human samples . Cancer Res (2014) ncbi
rat monoclonal (PCH101)
  • immunocytochemistry; human; 1:200
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in immunocytochemistry on human samples at 1:200. J Crohns Colitis (2014) ncbi
rat monoclonal (PCH101)
  • flow cytometry; African green monkey; 1:20; fig s6
In order to decipher how susequent acute infection is supressed in T cell responses after exposure to subinfectious hepatitis C virus, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on African green monkey samples at 1:20 (fig s6). Nat Med (2013) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 2b
In order to test if low immune activation contributes to the viremic slow progressor phenotype, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 2b). AIDS Res Hum Retroviruses (2013) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; 1:50; fig 1
In order to determine the localization of CD4 positive T cells subsets in the healthy intestine, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples at 1:50 (fig 1). PLoS ONE (2012) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 1
In order to use PI16 to identify a subset of migratory functional memory T regulatory cells, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 1). Cell Immunol (2012) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 3a
In order to test if low-dose interleukin-2 enhances T regulatory cells and suppresses chronic graft-versus-host disease, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 3a). N Engl J Med (2011) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; loading ...; fig 1a
In order to study the role of T regulatory cells in HIV infection, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 1a). J Virol (2011) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; human; 1:1600
In order to report the immune responses in the parietal pleura of patients with tuberculous pleurisy and compare them with nonspecific pleuritis, Invitrogen FOXP3 antibody (eBioscience, 144-777) was used in immunohistochemistry on human samples at 1:1600. PLoS ONE (2011) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; human; 1:40; fig S5B
In order to examine tumor and nonadjacent normal breast tissue from women with breast cancer, who either had or had not received neoadjuvant chemotherapy before surgery, Invitrogen FOXP3 antibody (eBioscience, 14-4777-82) was used in immunohistochemistry on human samples at 1:40 (fig S5B). Proc Natl Acad Sci U S A (2012) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig S5D
In order to examine tumor and nonadjacent normal breast tissue from women with breast cancer, who either had or had not received neoadjuvant chemotherapy before surgery, Invitrogen FOXP3 antibody (eBioscience, 15-4776-42) was used in flow cytometry on human samples (fig S5D). Proc Natl Acad Sci U S A (2012) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; rat; 50 ug/ml; tbl 2
In order to characterize bone marrow-derived mesenchymal stem cells from patients with ankylosing spondylitis, Invitrogen FOXP3 antibody (eBioscience, 236A) was used in flow cytometry on rat samples at 50 ug/ml (tbl 2). Arthritis Res Ther (2011) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig s1
In order to identify immunologic correlates of immune reconstitution inflammatory syndrome in HIV patients, Invitrogen FOXP3 antibody (eBioscience, (clone PCH101)) was used in flow cytometry on human samples (fig s1). Blood (2010) ncbi
rat monoclonal (PCH101)
  • immunohistochemistry; human; 1:200; fig 2
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in immunohistochemistry on human samples at 1:200 (fig 2). J Clin Endocrinol Metab (2010) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; mouse; fig 3
In order to compare the therapeutic efficacy of CD19-specific human primary T cells that constitutively express gamma(c)-cytokines, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on mouse samples (fig 3). Blood (2010) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 1
In order to study T regulatory cells in inflamed human liver samples, Invitrogen FOXP3 antibody (eBioscience, PCH 101) was used in flow cytometry on human samples (fig 1). J Immunol (2010) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
In order to identify biomarkers in the first synovial fluid aspirate obtained from children with oligoarticular juvenile idiopathic arthritis, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . Arthritis Rheum (2010) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
In order to report that human Tregs promote the generation of myeloid dendritic cells which abrogate post transplant lethality, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . PLoS Biol (2010) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 4
In order to discuss the role of T regulatory cells in systemic sclerosis and morphoea, Invitrogen FOXP3 antibody (eBiosciences, PCH101) was used in flow cytometry on human samples (fig 4). Br J Dermatol (2010) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 1
In order to examine the therapeutic potential of anti-CD137 mAb in lymphoma, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 1). Blood (2009) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry; human; 1:100; fig 8
Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in immunohistochemistry on human samples at 1:100 (fig 8). J Immunol (2009) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
In order to determine the role of CD59 on human CD4+ T cells, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . J Immunol (2009) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; tbl 1
In order to assess the regulatory function of human CD25+CD4+ T cells at various stages of maturity, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (tbl 1). Clin Dev Immunol (2008) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 4a
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 4a). Blood (2008) ncbi
rat monoclonal (PCH101)
  • western blot; human; 2 ug/ml
Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in western blot on human samples at 2 ug/ml. Cancer Res (2008) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human
Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples . Cancer Res (2008) ncbi
rat monoclonal (PCH101)
  • flow cytometry; African green monkey
In order to describe the in vitro effects of 5-(4-phenoxybutoxy)psoralen on T cells and its toxicity and pharmacokinetics in rhesus macaques, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on African green monkey samples . Exp Biol Med (Maywood) (2007) ncbi
mouse monoclonal (236a/E7)
  • flow cytometry; human; fig 4
  • immunohistochemistry; human; fig 6
In order to describe retinoids as positive regulatory factors for generating gut-homing FoxP3+ T cells in both humans and mice, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in flow cytometry on human samples (fig 4) and in immunohistochemistry on human samples (fig 6). J Immunol (2007) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 9A
In order to propose a model in which the gamma chain cytokines IL-2, IL-4, IL-7, and IL-15 maintain the optimal regulatory function of human CD4+ CD25+ T cells in a PI3K-dependent manner, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 9A). Int Immunol (2007) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
In order to observe a female patient with a polyautoimmune autoimmune enteropathy syndrome resembling a mild form of immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . Gastroenterology (2007) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human; fig 5
In order to determine the expression of CD39 in mouse and human T cells, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples (fig 5). Blood (2007) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
In order to determine the presence and functional characteristics of T regulatory cells in colonic lymphoid tissues in patients with ulcerative colitis, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . Inflamm Bowel Dis (2007) ncbi
mouse monoclonal (236a/E7)
  • immunohistochemistry - frozen section; human
  • flow cytometry; human
In order to report the expression of chemokine receptors on FOXP3+ T cells, Invitrogen FOXP3 antibody (eBioscience, 236A/E7) was used in immunohistochemistry - frozen section on human samples and in flow cytometry on human samples . J Immunol (2006) ncbi
rat monoclonal (PCH101)
  • flow cytometry; human
In order to report the expression of chemokine receptors on FOXP3+ T cells, Invitrogen FOXP3 antibody (eBioscience, PCH101) was used in flow cytometry on human samples . J Immunol (2006) ncbi
BioLegend
mouse monoclonal (150D)
  • flow cytometry; mouse; fig 5g
BioLegend FOXP3 antibody (BioLegend, 150D) was used in flow cytometry on mouse samples (fig 5g). Sci Adv (2021) ncbi
mouse monoclonal (259D)
  • flow cytometry; human; loading ...; fig 6b
BioLegend FOXP3 antibody (BioLegend, 320 208) was used in flow cytometry on human samples (fig 6b). Adv Sci (Weinh) (2021) ncbi
mouse monoclonal (259D)
  • immunohistochemistry - paraffin section; human; 1:50; loading ...; fig s1a
BioLegend FOXP3 antibody (Biolegend, 320201) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig s1a). Front Cell Dev Biol (2021) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse; 1:100; loading ...; fig 1a
BioLegend FOXP3 antibody (Biolegend, 150D) was used in flow cytometry on mouse samples at 1:100 (fig 1a). Nat Commun (2021) ncbi
mouse monoclonal (259D)
  • flow cytometry; human; loading ...; fig 3a
BioLegend FOXP3 antibody (BioLegend, 320214) was used in flow cytometry on human samples (fig 3a). Immunity (2021) ncbi
mouse monoclonal (206D)
  • immunohistochemistry; mouse; loading ...; fig s1l
BioLegend FOXP3 antibody (BioLegend, 320114) was used in immunohistochemistry on mouse samples (fig s1l). Cell (2020) ncbi
mouse monoclonal (206D)
  • immunohistochemistry - paraffin section; human; loading ...; fig 3
BioLegend FOXP3 antibody (BioLegend, 206D) was used in immunohistochemistry - paraffin section on human samples (fig 3). Front Immunol (2020) ncbi
mouse monoclonal (206D)
  • immunohistochemistry - paraffin section; human; 1:50; loading ...; fig 2e
  • immunohistochemistry; human; 1:50; loading ...; fig 2f
BioLegend FOXP3 antibody (Biolegend, 320102) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 2e) and in immunohistochemistry on human samples at 1:50 (fig 2f). Nature (2020) ncbi
mouse monoclonal (150D)
  • flow cytometry; human; 1:100; loading ...; fig 7a
BioLegend FOXP3 antibody (Biolegend, 320012) was used in flow cytometry on human samples at 1:100 (fig 7a). elife (2019) ncbi
mouse monoclonal (150D)
  • flow cytometry; human; loading ...; fig 4f
BioLegend FOXP3 antibody (Biolegend, 320014) was used in flow cytometry on human samples (fig 4f). Cell Mol Gastroenterol Hepatol (2020) ncbi
mouse monoclonal (206D)
  • immunohistochemistry; human; loading ...; fig 3c
BioLegend FOXP3 antibody (BioLegend, 320102) was used in immunohistochemistry on human samples (fig 3c). Cell (2019) ncbi
mouse monoclonal (259D)
  • flow cytometry; human; 1:50; fig 1d
BioLegend FOXP3 antibody (Biolegend, 320213) was used in flow cytometry on human samples at 1:50 (fig 1d). Nat Commun (2019) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse; 1:500; loading ...; fig e2f
BioLegend FOXP3 antibody (Biolegend, 320008) was used in flow cytometry on mouse samples at 1:500 (fig e2f). Nature (2019) ncbi
mouse monoclonal (259D)
  • flow cytometry; human; loading ...; fig s8c
BioLegend FOXP3 antibody (BioLegend, 259D) was used in flow cytometry on human samples (fig s8c). Nat Immunol (2019) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse; 1:40; loading ...; fig 6s1
BioLegend FOXP3 antibody (Biolegend, 320007) was used in flow cytometry on mouse samples at 1:40 (fig 6s1). elife (2019) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse; loading ...; fig 3b
BioLegend FOXP3 antibody (Biolegend, 150D) was used in flow cytometry on mouse samples (fig 3b). Int J Cancer (2019) ncbi
mouse monoclonal (259D)
  • flow cytometry; human; loading ...; fig 5a
BioLegend FOXP3 antibody (BioLegend, 259D) was used in flow cytometry on human samples (fig 5a). Front Immunol (2018) ncbi
mouse monoclonal (259D)
  • flow cytometry; human; 1:10; loading ...; fig 2a
BioLegend FOXP3 antibody (Biolegend, 320212) was used in flow cytometry on human samples at 1:10 (fig 2a). Nat Med (2019) ncbi
mouse monoclonal (259D)
  • other; human; loading ...; fig 2a
BioLegend FOXP3 antibody (BioLegend, 320208) was used in other on human samples (fig 2a). J Clin Invest (2018) ncbi
mouse monoclonal (150D)
  • flow cytometry; rhesus macaque; loading ...; fig 2g
BioLegend FOXP3 antibody (Biolegend, 150D) was used in flow cytometry on rhesus macaque samples (fig 2g). J Virol (2019) ncbi
mouse monoclonal (150D)
  • flow cytometry; human; loading ...; fig 3c
BioLegend FOXP3 antibody (Biolegend, 320013) was used in flow cytometry on human samples (fig 3c). Biosci Rep (2018) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; loading ...; fig 1
BioLegend FOXP3 antibody (BioLegend, 206D) was used in flow cytometry on human samples (fig 1). Am J Trop Med Hyg (2018) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse; loading ...; fig s2a
BioLegend FOXP3 antibody (BioLegend, 150D) was used in flow cytometry on mouse samples (fig s2a). J Clin Invest (2018) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; loading ...; fig 3b
  • immunohistochemistry; human; loading ...; fig 3a
BioLegend FOXP3 antibody (Biolegend, 206D) was used in flow cytometry on human samples (fig 3b) and in immunohistochemistry on human samples (fig 3a). J Immunol (2018) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; loading ...; fig 4d
In order to detail MAIT cell responses to various microorganisms and cytokines, BioLegend FOXP3 antibody (BioLegend, 206D) was used in flow cytometry on human samples (fig 4d). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse; 1:50; loading ...; fig 5b
BioLegend FOXP3 antibody (Biolegend, 150D) was used in flow cytometry on mouse samples at 1:50 (fig 5b). Nat Commun (2017) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse; loading ...; fig 4c
In order to discover that SIRPalpha is highly expressed in human renal cell carcinoma and melanoma, BioLegend FOXP3 antibody (BioLegend, 150D) was used in flow cytometry on mouse samples (fig 4c). JCI Insight (2017) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; loading ...; fig 4d
In order to investigate the roles of CD16+ monocytes in T-cell activation and B-cell responses in systemic lupus erythematosus, BioLegend FOXP3 antibody (Biolegend, 320114) was used in flow cytometry on human samples (fig 4d). Front Immunol (2016) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; loading ...; fig 1b
BioLegend FOXP3 antibody (BioLegend, 206D) was used in flow cytometry on human samples (fig 1b). Cell Death Dis (2016) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; loading ...; fig 2b
In order to investigate the basis for T regulatory cell accumulation in melanoma, BioLegend FOXP3 antibody (Biolegend, 206D) was used in flow cytometry on human samples (fig 2b). Cancer Res (2016) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; fig s2
BioLegend FOXP3 antibody (Biolegend, 206D) was used in flow cytometry on human samples (fig s2). PLoS Pathog (2016) ncbi
mouse monoclonal (206D)
  • immunohistochemistry - paraffin section; human; 5 ug/ml; loading ...; tbl 2
In order to measure FoxP3 and IL17 expression in patients with oral lichen planus, BioLegend FOXP3 antibody (Biolegend, 320102) was used in immunohistochemistry - paraffin section on human samples at 5 ug/ml (tbl 2). Pathology (2016) ncbi
mouse monoclonal (259D)
  • flow cytometry; human; 1:20; fig st2
BioLegend FOXP3 antibody (Biolegend, 320216) was used in flow cytometry on human samples at 1:20 (fig st2). Nat Commun (2016) ncbi
mouse monoclonal (150D)
  • chromatin immunoprecipitation; mouse; fig 4
In order to study the requisite for the function of regulatory T cells known as phosphatase PP2A, BioLegend FOXP3 antibody (Biolegend, 150D) was used in chromatin immunoprecipitation on mouse samples (fig 4). Nat Immunol (2016) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse; fig 5d
BioLegend FOXP3 antibody (BioLegend, 150D) was used in flow cytometry on mouse samples (fig 5d). Gastroenterology (2016) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; loading ...; fig 6b
In order to discuss the impact of filaggrin mutations on the development of atopic dermatitis, BioLegend FOXP3 antibody (BioLegend, 206D) was used in flow cytometry on human samples (fig 6b). J Allergy Clin Immunol (2016) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse; fig 6
In order to study how a novel multi-drug metronomic chemotherapy can delay tumor growth in mice significantly, BioLegend FOXP3 antibody (BioLegend, 150D) was used in flow cytometry on mouse samples (fig 6). J Transl Med (2016) ncbi
mouse monoclonal (150D)
  • western blot; mouse; 1:500; fig 4
BioLegend FOXP3 antibody (Biolegend, 150D) was used in western blot on mouse samples at 1:500 (fig 4). PLoS ONE (2015) ncbi
mouse monoclonal (150D)
  • flow cytometry; human
BioLegend FOXP3 antibody (Biolegend, 320014) was used in flow cytometry on human samples . Mol Oncol (2015) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse; fig 2
In order to study engineered anti-melanoma vaccines that modulate cytokine priming and silence PD-L1 simultaneously by use of ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy, BioLegend FOXP3 antibody (BioLegend, 320014) was used in flow cytometry on mouse samples (fig 2). Oncoimmunology (2014) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; fig 6
In order to report the phase I trial results of CDX-301, BioLegend FOXP3 antibody (BioLegend, 206D) was used in flow cytometry on human samples (fig 6). Bone Marrow Transplant (2015) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; tbl s1
BioLegend FOXP3 antibody (Biolegend, 206D) was used in flow cytometry on human samples (tbl s1). PLoS ONE (2015) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; fig 6
BioLegend FOXP3 antibody (BioLegend, 206D) was used in flow cytometry on human samples (fig 6). PLoS ONE (2015) ncbi
mouse monoclonal (150D)
  • flow cytometry; human; fig 5
BioLegend FOXP3 antibody (Biolegend, 150D) was used in flow cytometry on human samples (fig 5). J Cell Mol Med (2015) ncbi
mouse monoclonal (206D)
  • immunohistochemistry; human; fig 2
BioLegend FOXP3 antibody (320102, 320102) was used in immunohistochemistry on human samples (fig 2). Clin Cancer Res (2015) ncbi
mouse monoclonal (259D)
  • flow cytometry; mouse; fig 8
BioLegend FOXP3 antibody (BioLegend, 320212) was used in flow cytometry on mouse samples (fig 8). J Immunol (2015) ncbi
mouse monoclonal (206D)
  • flow cytometry; human; loading ...; fig 1
In order to investigate the role of granzyme B in T regulatory cell resistance, BioLegend FOXP3 antibody (BioLegend, 206D) was used in flow cytometry on human samples (fig 1). J Immunol (2015) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse
BioLegend FOXP3 antibody (BioLegend, 150D) was used in flow cytometry on mouse samples . J Immunol (2014) ncbi
mouse monoclonal (206D)
BioLegend FOXP3 antibody (Biolegend, 206D) was used . PLoS ONE (2014) ncbi
mouse monoclonal (206D)
BioLegend FOXP3 antibody (BioLegend, 320102) was used . Cancer Immunol Res (2014) ncbi
mouse monoclonal (150D)
In order to study the modulation of CD4 T-cell senescence and cytokine production and the roles played by Menin and Bach2, BioLegend FOXP3 antibody (BioLegend, 150D) was used . Nat Commun (2014) ncbi
mouse monoclonal (150D)
  • flow cytometry; mouse
BioLegend FOXP3 antibody (Biolegend, 320013) was used in flow cytometry on mouse samples . Exp Parasitol (2014) ncbi
mouse monoclonal (150D)
  • immunocytochemistry; human; 1:50
BioLegend FOXP3 antibody (BioLegend, 150D) was used in immunocytochemistry on human samples at 1:50. Nephrology (Carlton) (2014) ncbi
Articles Reviewed
  1. Horiuchi S, Wu H, Liu W, Schmitt N, Provot J, Liu Y, et al. Tox2 is required for the maintenance of GC TFH cells and the generation of memory TFH cells. Sci Adv. 2021;7:eabj1249 pubmed publisher
  2. Kim G, Kim W, Lim S, Lee H, Koo J, Nam K, et al. In Vivo Induction of Regulatory T Cells Via CTLA-4 Signaling Peptide to Control Autoimmune Encephalomyelitis and Prevent Disease Relapse. Adv Sci (Weinh). 2021;8:2004973 pubmed publisher
  3. Zhang J, Qi J, Wei H, Lei Y, Yu H, Liu N, et al. TGFβ1 in Cancer-Associated Fibroblasts Is Associated With Progression and Radiosensitivity in Small-Cell Lung Cancer. Front Cell Dev Biol. 2021;9:667645 pubmed publisher
  4. Amoozgar Z, Kloepper J, Ren J, Tay R, Kazer S, Kiner E, et al. Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas. Nat Commun. 2021;12:2582 pubmed publisher
  5. Szabo P, Dogra P, Gray J, Wells S, Connors T, Weisberg S, et al. Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19. Immunity. 2021;54:797-814.e6 pubmed publisher
  6. Luo B, Zhan Y, Luo M, Dong H, Liu J, Lin Y, et al. Engineering of α-PD-1 antibody-expressing long-lived plasma cells by CRISPR/Cas9-mediated targeted gene integration. Cell Death Dis. 2020;11:973 pubmed publisher
  7. Pasciuto E, Burton O, Roca C, Lagou V, Rajan W, Theys T, et al. Microglia Require CD4 T Cells to Complete the Fetal-to-Adult Transition. Cell. 2020;182:625-640.e24 pubmed publisher
  8. Kuhny M, Forbes L, Çakan E, Vega Loza A, Kostiuk V, Dinesh R, et al. Disease-associated CTNNBL1 mutation impairs somatic hypermutation by decreasing nuclear AID. J Clin Invest. 2020;: pubmed publisher
  9. Hanaoka H, Nishimoto T, Okazaki Y, Takeuchi T, Kuwana M. A unique thymus-derived regulatory T cell subset associated with systemic lupus erythematosus. Arthritis Res Ther. 2020;22:88 pubmed publisher
  10. Herrera Rios D, Mughal S, Teuber Hanselmann S, Pierscianek D, Sucker A, Jansen P, et al. Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain. Front Immunol. 2020;11:120 pubmed publisher
  11. Boudewijns S, Bloemendal M, de Haas N, Westdorp H, Bol K, Schreibelt G, et al. Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. Cancer Immunol Immunother. 2020;69:477-488 pubmed publisher
  12. Helmink B, Reddy S, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577:549-555 pubmed publisher
  13. Martínez Fábregas J, Wilmes S, Wang L, Hafer M, Pohler E, Lokau J, et al. Kinetics of cytokine receptor trafficking determine signaling and functional selectivity. elife. 2019;8: pubmed publisher
  14. Di Blasi D, Boldanova T, Mori L, Terracciano L, Heim M, De Libero G. Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol. 2020;9:195-218 pubmed publisher
  15. Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, et al. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell. 2019;178:795-806.e12 pubmed publisher
  16. Leclerc M, Voilin E, Gros G, Corgnac S, de Montpreville V, Validire P, et al. Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1. Nat Commun. 2019;10:3345 pubmed publisher
  17. Lim S, Kim J, Jeon S, Shin M, Kwon J, Kim T, et al. Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients. Front Immunol. 2019;10:496 pubmed publisher
  18. Wagner J, Rapsomaniki M, Chevrier S, Anzeneder T, Langwieder C, Dykgers A, et al. A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. Cell. 2019;177:1330-1345.e18 pubmed publisher
  19. Binnewies M, Mujal A, Pollack J, Combes A, Hardison E, Barry K, et al. Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity. Cell. 2019;177:556-571.e16 pubmed publisher
  20. Thompson P, Shah A, Ntranos V, Van Gool F, Atkinson M, Bhushan A. Targeted Elimination of Senescent Beta Cells Prevents Type 1 Diabetes. Cell Metab. 2019;29:1045-1060.e10 pubmed publisher
  21. Han D, Liu J, Chen C, Dong L, Liu Y, Chang R, et al. Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells. Nature. 2019;566:270-274 pubmed publisher
  22. Wen Z, Jin K, Shen Y, Yang Z, Li Y, Wu B, et al. N-myristoyltransferase deficiency impairs activation of kinase AMPK and promotes synovial tissue inflammation. Nat Immunol. 2019;20:313-325 pubmed publisher
  23. Lavoie S, Conway K, Lassen K, Jijon H, Pan H, Chun E, et al. The Crohn's disease polymorphism, ATG16L1 T300A, alters the gut microbiota and enhances the local Th1/Th17 response. elife. 2019;8: pubmed publisher
  24. Ha D, Tanaka A, Kibayashi T, Tanemura A, Sugiyama D, Wing J, et al. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody. Proc Natl Acad Sci U S A. 2019;116:609-618 pubmed publisher
  25. Cornelissen L, Blanas A, van der Horst J, Kruijssen L, Zaal A, O Toole T, et al. Disruption of sialic acid metabolism drives tumor growth by augmenting CD8+ T cell apoptosis. Int J Cancer. 2019;144:2290-2302 pubmed publisher
  26. Richardson J, Armbruster N, Günter M, Henes J, Autenrieth S. Staphylococcus aureus PSM Peptides Modulate Human Monocyte-Derived Dendritic Cells to Prime Regulatory T Cells. Front Immunol. 2018;9:2603 pubmed publisher
  27. Williams P, Basu S, Garcia Manero G, Hourigan C, Oetjen K, Cortes J, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019;125:1470-1481 pubmed publisher
  28. Wagner D, Amini L, Wendering D, Burkhardt L, Akyüz L, Reinke P, et al. High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population. Nat Med. 2019;25:242-248 pubmed publisher
  29. Kuranda K, Jean Alphonse P, Leborgne C, Hardet R, Collaud F, Marmier S, et al. Exposure to wild-type AAV drives distinct capsid immunity profiles in humans. J Clin Invest. 2018;128:5267-5279 pubmed publisher
  30. Hoang T, Harper J, Pino M, Wang H, Micci L, King C, et al. Bone Marrow-Derived CD4+ T Cells Are Depleted in Simian Immunodeficiency Virus-Infected Macaques and Contribute to the Size of the Replication-Competent Reservoir. J Virol. 2019;93: pubmed publisher
  31. Patel N, Vukmanovic Stejic M, Suárez Fariñas M, Chambers E, Sandhu D, Fuentes Duculan J, et al. Impact of Zostavax Vaccination on T-Cell Accumulation and Cutaneous Gene Expression in the Skin of Older Humans After Varicella Zoster Virus Antigen-Specific Challenge. J Infect Dis. 2018;218:S88-S98 pubmed publisher
  32. Zhao S, Ding J, Wang S, Li C, Guo P, Zhang M, et al. Decreased expression of circulating Aire and increased Tfh/Tfr cells in myasthenia gravis patients. Biosci Rep. 2018;38: pubmed publisher
  33. Sayin I, Radtke A, Vella L, Jin W, Wherry E, Buggert M, et al. Spatial distribution and function of T follicular regulatory cells in human lymph nodes. J Exp Med. 2018;215:1531-1542 pubmed publisher
  34. Ondigo B, Ndombi E, Nicholson S, Oguso J, Carter J, Kittur N, et al. Functional Studies of T Regulatory Lymphocytes in Human Schistosomiasis in Western Kenya. Am J Trop Med Hyg. 2018;98:1770-1781 pubmed publisher
  35. Varelias A, Bunting M, Ormerod K, Koyama M, Olver S, Straube J, et al. Recipient mucosal-associated invariant T cells control GVHD within the colon. J Clin Invest. 2018;128:1919-1936 pubmed publisher
  36. Han Y, Liu Q, Hou J, Gu Y, Zhang Y, Chen Z, et al. Tumor-Induced Generation of Splenic Erythroblast-like Ter-Cells Promotes Tumor Progression. Cell. 2018;173:634-648.e12 pubmed publisher
  37. Kawano Y, Zavidij O, Park J, Moschetta M, Kokubun K, Mouhieddine T, et al. Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. J Clin Invest. 2018;128:2487-2499 pubmed publisher
  38. Hsieh W, Hsu T, Chang Y, Lai M. IL-6 receptor blockade corrects defects of XIAP-deficient regulatory T cells. Nat Commun. 2018;9:463 pubmed publisher
  39. Amodio D, Cotugno N, Macchiarulo G, Rocca S, Dimopoulos Y, Castrucci M, et al. Quantitative Multiplexed Imaging Analysis Reveals a Strong Association between Immunogen-Specific B Cell Responses and Tonsillar Germinal Center Immune Dynamics in Children after Influenza Vaccination. J Immunol. 2018;200:538-550 pubmed publisher
  40. Liaskou E, Jeffery L, Chanouzas D, Soskic B, Seldin M, Harper L, et al. Genetic variation at the CD28 locus and its impact on expansion of pro-inflammatory CD28 negative T cells in healthy individuals. Sci Rep. 2017;7:7652 pubmed publisher
  41. Chew V, Lai L, Pan L, Lim C, Li J, Ong R, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A. 2017;114:E5900-E5909 pubmed publisher
  42. Dias J, Leeansyah E, Sandberg J. Multiple layers of heterogeneity and subset diversity in human MAIT cell responses to distinct microorganisms and to innate cytokines. Proc Natl Acad Sci U S A. 2017;114:E5434-E5443 pubmed publisher
  43. Garcia Hernandez M, Uribe Uribe N, Espinosa González R, Kast W, Khader S, Rangel Moreno J. A Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression. Front Immunol. 2017;8:563 pubmed publisher
  44. Hasan Z, Koizumi S, Sasaki D, Yamada H, Arakaki N, Fujihara Y, et al. JunB is essential for IL-23-dependent pathogenicity of Th17 cells. Nat Commun. 2017;8:15628 pubmed publisher
  45. Ventura E, Weller M, Burghardt I. Cutting Edge: ERK1 Mediates the Autocrine Positive Feedback Loop of TGF-? and Furin in Glioma-Initiating Cells. J Immunol. 2017;198:4569-4574 pubmed publisher
  46. Zanin Zhorov A, Weiss J, Trzeciak A, Chen W, Zhang J, Nyuydzefe M, et al. Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10. J Immunol. 2017;198:3809-3814 pubmed publisher
  47. Melis D, Carbone F, Minopoli G, La Rocca C, Perna F, De Rosa V, et al. Cutting Edge: Increased Autoimmunity Risk in Glycogen Storage Disease Type 1b Is Associated with a Reduced Engagement of Glycolysis in T Cells and an Impaired Regulatory T Cell Function. J Immunol. 2017;198:3803-3808 pubmed publisher
  48. Su S, Liao J, Liu J, Huang D, He C, Chen F, et al. Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer. Cell Res. 2017;27:461-482 pubmed publisher
  49. Szabo P, Goswami A, Mazzuca D, Kim K, O Gorman D, Hess D, et al. Rapid and Rigorous IL-17A Production by a Distinct Subpopulation of Effector Memory T Lymphocytes Constitutes a Novel Mechanism of Toxic Shock Syndrome Immunopathology. J Immunol. 2017;198:2805-2818 pubmed publisher
  50. Jeffery H, Jeffery L, Lutz P, Corrigan M, Webb G, Hirschfield G, et al. Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseases. Clin Exp Immunol. 2017;188:394-411 pubmed publisher
  51. Yanagita T, Murata Y, Tanaka D, Motegi S, Arai E, Daniwijaya E, et al. Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy. JCI Insight. 2017;2:e89140 pubmed publisher
  52. Kim J, Kwon C, Joh J, Sinn D, Choi G, Park J, et al. Differences in Peripheral Blood Lymphocytes between Brand-Name and Generic Tacrolimus Used in Stable Liver Transplant Recipients. Med Princ Pract. 2017;26:221-228 pubmed publisher
  53. Boardman D, Philippeos C, Fruhwirth G, Ibrahim M, Hannen R, Cooper D, et al. Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection. Am J Transplant. 2017;17:931-943 pubmed publisher
  54. Zhu H, Hu F, Sun X, Zhang X, Zhu L, Liu X, et al. CD16+ Monocyte Subset Was Enriched and Functionally Exacerbated in Driving T-Cell Activation and B-Cell Response in Systemic Lupus Erythematosus. Front Immunol. 2016;7:512 pubmed
  55. Wei C, Mei J, Tang L, Liu Y, Li D, Li M, et al. 1-Methyl-tryptophan attenuates regulatory T cells differentiation due to the inhibition of estrogen-IDO1-MRC2 axis in endometriosis. Cell Death Dis. 2016;7:e2489 pubmed publisher
  56. Weingartner E, Courneya J, Keegan A, Golding A. A novel method for assaying human regulatory T cell direct suppression of B cell effector function. J Immunol Methods. 2017;441:1-7 pubmed publisher
  57. Nagase H, Takeoka T, Urakawa S, Morimoto Okazawa A, Kawashima A, Iwahori K, et al. ICOS+ Foxp3+ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori. Int J Cancer. 2017;140:686-695 pubmed publisher
  58. Klarquist J, Tobin K, Farhangi Oskuei P, Henning S, Fernandez M, Dellacecca E, et al. Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma. Cancer Res. 2016;76:6230-6240 pubmed
  59. Pachnio A, Ciáurriz M, Begum J, Lal N, Zuo J, Beggs A, et al. Cytomegalovirus Infection Leads to Development of High Frequencies of Cytotoxic Virus-Specific CD4+ T Cells Targeted to Vascular Endothelium. PLoS Pathog. 2016;12:e1005832 pubmed publisher
  60. Javvadi L, Parachuru V, Milne T, Seymour G, Rich A. Regulatory T-cells and IL17A(+) cells infiltrate oral lichen planus lesions. Pathology. 2016;48:564-73 pubmed publisher
  61. Chopra M, Biehl M, Steinfatt T, Brandl A, Kums J, Amich J, et al. Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion. J Exp Med. 2016;213:1881-900 pubmed publisher
  62. Cheng H, Gaddis D, Wu R, McSkimming C, Haynes L, Taylor A, et al. Loss of ABCG1 influences regulatory T cell differentiation and atherosclerosis. J Clin Invest. 2016;126:3236-46 pubmed publisher
  63. Chen H, Händel N, Ngeow J, Muller J, Huhn M, Yang H, et al. Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells. J Allergy Clin Immunol. 2017;139:607-620.e15 pubmed publisher
  64. Miyan M, Schmidt Mende J, Kiessling R, Poschke I, de Boniface J. Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer. J Transl Med. 2016;14:227 pubmed publisher
  65. Baras A, Drake C, Liu J, Gandhi N, Kates M, Hoque M, et al. The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. Oncoimmunology. 2016;5:e1134412 pubmed publisher
  66. Brinkman C, Iwami D, Hritzo M, Xiong Y, Ahmad S, Simon T, et al. Treg engage lymphotoxin beta receptor for afferent lymphatic transendothelial migration. Nat Commun. 2016;7:12021 pubmed publisher
  67. Chu H, Khosravi A, Kusumawardhani I, Kwon A, Vasconcelos A, Cunha L, et al. Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. Science. 2016;352:1116-20 pubmed publisher
  68. Akyol Erikci A, Karagoz B, Bilgi O. Regulatory T Cells in Patients with Idiopathic Thrombocytopenic Purpura. Turk J Haematol. 2016;33:153-5 pubmed publisher
  69. Stikvoort A, Sundin M, Uzunel M, Gertow J, Sundberg B, Schaffer M, et al. Long-Term Stable Mixed Chimerism after Hematopoietic Stem Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant?. PLoS ONE. 2016;11:e0154737 pubmed publisher
  70. Cook A, McDonnell A, Lake R, Nowak A. Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies. Oncoimmunology. 2016;5:e1066062 pubmed
  71. Goldstein J, Burlion A, Zaragoza B, Sendeyo K, Polansky J, Huehn J, et al. Inhibition of the JAK/STAT Signaling Pathway in Regulatory T Cells Reveals a Very Dynamic Regulation of Foxp3 Expression. PLoS ONE. 2016;11:e0153682 pubmed publisher
  72. Zwang N, Zhang R, Germana S, Fan M, Hastings W, Cao A, et al. Selective Sparing of Human Tregs by Pharmacologic Inhibitors of the Phosphatidylinositol 3-Kinase and MEK Pathways. Am J Transplant. 2016;16:2624-38 pubmed publisher
  73. Macdonald K, Hoeppli R, Huang Q, Gillies J, Luciani D, Orban P, et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest. 2016;126:1413-24 pubmed publisher
  74. Apostolidis S, Rodríguez Rodríguez N, Suárez Fueyo A, Dioufa N, Ozcan E, Crispín J, et al. Phosphatase PP2A is requisite for the function of regulatory T cells. Nat Immunol. 2016;17:556-64 pubmed publisher
  75. Seifert L, Werba G, Tiwari S, Giao Ly N, Nguy S, Alothman S, et al. Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice. Gastroenterology. 2016;150:1659-1672.e5 pubmed publisher
  76. McGranahan N, Furness A, Rosenthal R, Ramskov S, Lyngaa R, Saini S, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463-9 pubmed publisher
  77. Leitch C, Natafji E, Yu C, Abdul Ghaffar S, Madarasingha N, Venables Z, et al. Filaggrin-null mutations are associated with increased maturation markers on Langerhans cells. J Allergy Clin Immunol. 2016;138:482-490.e7 pubmed publisher
  78. Tagliamonte M, Petrizzo A, Napolitano M, Luciano A, Rea D, Barbieri A, et al. A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice. J Transl Med. 2016;14:58 pubmed publisher
  79. Procaccini C, Carbone F, Di Silvestre D, Brambilla F, De Rosa V, Galgani M, et al. The Proteomic Landscape of Human Ex Vivo Regulatory and Conventional T Cells Reveals Specific Metabolic Requirements. Immunity. 2016;44:406-21 pubmed publisher
  80. Legorreta Haquet M, Chávez Rueda K, Chávez Sánchez L, Cervera Castillo H, Zenteno Galindo E, Barile Fabris L, et al. Function of Treg Cells Decreased in Patients With Systemic Lupus Erythematosus Due To the Effect of Prolactin. Medicine (Baltimore). 2016;95:e2384 pubmed publisher
  81. James E, Gates T, LaFond R, Yamamoto S, Ni C, Mai D, et al. Neuroinvasive West Nile Infection Elicits Elevated and Atypically Polarized T Cell Responses That Promote a Pathogenic Outcome. PLoS Pathog. 2016;12:e1005375 pubmed publisher
  82. Younis R, Han K, Webb T. Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells. J Immunol. 2016;196:1419-29 pubmed publisher
  83. Kobayashi S, Watanabe T, Suzuki R, Furu M, Ito H, Ito J, et al. TGF-β induces the differentiation of human CXCL13-producing CD4(+) T cells. Eur J Immunol. 2016;46:360-71 pubmed publisher
  84. Vierboom M, Breedveld E, Kap Y, Mary C, Poirier N, t Hart B, et al. Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis. Clin Exp Immunol. 2016;183:405-18 pubmed publisher
  85. Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, Unger K, et al. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol. 2015;16:1235-44 pubmed publisher
  86. Miles B, Miller S, Folkvord J, Kimball A, Chamanian M, Meditz A, et al. Follicular regulatory T cells impair follicular T helper cells in HIV and SIV infection. Nat Commun. 2015;6:8608 pubmed publisher
  87. Scottà C, Fanelli G, Hoong S, Romano M, Lamperti E, Sukthankar M, et al. Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells. Haematologica. 2016;101:91-100 pubmed publisher
  88. Liu K, Yang K, Wu B, Chen H, Chen X, Chen X, et al. Tumor-Infiltrating Immune Cells Are Associated With Prognosis of Gastric Cancer. Medicine (Baltimore). 2015;94:e1631 pubmed publisher
  89. Bézie S, Picarda E, Ossart J, Tesson L, Usal C, Renaudin K, et al. IL-34 is a Treg-specific cytokine and mediates transplant tolerance. J Clin Invest. 2015;125:3952-64 pubmed publisher
  90. Broos C, van Nimwegen M, Kleinjan A, Ten Berge B, Muskens F, In t Veen J, et al. Impaired survival of regulatory T cells in pulmonary sarcoidosis. Respir Res. 2015;16:108 pubmed publisher
  91. Suradhat S, Wongyanin P, Kesdangsakonwut S, Teankum K, Lumyai M, Triyarach S, et al. A novel DNA vaccine for reduction of PRRSV-induced negative immunomodulatory effects: A proof of concept. Vaccine. 2015;33:3997-4003 pubmed publisher
  92. Prata T, Bonin C, Ferreira A, Padovani C, Fernandes C, Machado A, et al. Local immunosuppression induced by high viral load of human papillomavirus: characterization of cellular phenotypes producing interleukin-10 in cervical neoplastic lesions. Immunology. 2015;146:113-21 pubmed publisher
  93. Horn T, Laus J, Seitz A, Maurer T, Schmid S, Wolf P, et al. The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer. World J Urol. 2016;34:181-7 pubmed publisher
  94. Castiglioni A, Corna G, Rigamonti E, Basso V, Vezzoli M, Monno A, et al. FOXP3+ T Cells Recruited to Sites of Sterile Skeletal Muscle Injury Regulate the Fate of Satellite Cells and Guide Effective Tissue Regeneration. PLoS ONE. 2015;10:e0128094 pubmed publisher
  95. Wang Z, Wei M, Zhang H, Chen H, Germana S, Huang C, et al. Diphtheria-toxin based anti-human CCR4 immunotoxin for targeting human CCR4(+) cells in vivo. Mol Oncol. 2015;9:1458-70 pubmed publisher
  96. Liechtenstein T, Perez Janices N, Blanco Luquin I, Goyvaerts C, Schwarze J, Dufait I, et al. Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy. Oncoimmunology. 2014;3:e945378 pubmed
  97. Boer M, Prins C, van Meijgaarden K, van Dissel J, Ottenhoff T, Joosten S. Mycobacterium bovis BCG Vaccination Induces Divergent Proinflammatory or Regulatory T Cell Responses in Adults. Clin Vaccine Immunol. 2015;22:778-88 pubmed publisher
  98. DaFonseca S, Niessl J, Pouvreau S, Wacleche V, Gosselin A, Cleret Buhot A, et al. Impaired Th17 polarization of phenotypically naive CD4(+) T-cells during chronic HIV-1 infection and potential restoration with early ART. Retrovirology. 2015;12:38 pubmed publisher
  99. Anandasabapathy N, Breton G, Hurley A, Caskey M, Trumpfheller C, Sarma P, et al. Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. Bone Marrow Transplant. 2015;50:924-30 pubmed publisher
  100. Weinberg A, Muresan P, Richardson K, Fenton T, Domínguez T, Bloom A, et al. Determinants of vaccine immunogenicity in HIV-infected pregnant women: analysis of B and T cell responses to pandemic H1N1 monovalent vaccine. PLoS ONE. 2015;10:e0122431 pubmed publisher
  101. Rochman Y, Yukawa M, Kartashov A, Barski A. Functional characterization of human T cell hyporesponsiveness induced by CTLA4-Ig. PLoS ONE. 2015;10:e0122198 pubmed publisher
  102. Romani R, Pirisinu I, Calvitti M, Pallotta M, Gargaro M, Bistoni G, et al. Stem cells from human amniotic fluid exert immunoregulatory function via secreted indoleamine 2,3-dioxygenase1. J Cell Mol Med. 2015;19:1593-605 pubmed publisher
  103. Obiero J, Shekalaghe S, Hermsen C, Mpina M, Bijker E, Roestenberg M, et al. Impact of malaria preexposure on antiparasite cellular and humoral immune responses after controlled human malaria infection. Infect Immun. 2015;83:2185-96 pubmed publisher
  104. Bowcutt R, Malter L, Chen L, Wolff M, Robertson I, Rifkin D, et al. Isolation and cytokine analysis of lamina propria lymphocytes from mucosal biopsies of the human colon. J Immunol Methods. 2015;421:27-35 pubmed publisher
  105. Zsiros E, Duttagupta P, Dangaj D, Li H, Frank R, Garrabrant T, et al. The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy. Clin Cancer Res. 2015;21:2840-50 pubmed publisher
  106. Severson J, Serracino H, Mateescu V, Raeburn C, McIntyre R, Sams S, et al. PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunol Res. 2015;3:620-30 pubmed publisher
  107. Valle A, Barbagiovanni G, Jofra T, Stabilini A, Pérol L, Baeyens A, et al. Heterogeneous CD3 expression levels in differing T cell subsets correlate with the in vivo anti-CD3-mediated T cell modulation. J Immunol. 2015;194:2117-27 pubmed publisher
  108. Bhela S, Kempsell C, Manohar M, Dominguez Villar M, Griffin R, Bhatt P, et al. Nonapoptotic and extracellular activity of granzyme B mediates resistance to regulatory T cell (Treg) suppression by HLA-DR-CD25hiCD127lo Tregs in multiple sclerosis and in response to IL-6. J Immunol. 2015;194:2180-9 pubmed publisher
  109. Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, et al. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res. 2015;25:208-24 pubmed publisher
  110. Nguyen L, Pan J, Dinh T, Hadeiba H, O Hara E, Ebtikar A, et al. Role and species-specific expression of colon T cell homing receptor GPR15 in colitis. Nat Immunol. 2015;16:207-213 pubmed publisher
  111. Wu Y, Du Z, Cai Y, Peng W, Zheng G, Zheng G, et al. Effective expansion of forkhead box P3⁺ regulatory T cells via early secreted antigenic target 6 and antigen 85 complex B from Mycobacterium tuberculosis. Mol Med Rep. 2015;11:3134-42 pubmed publisher
  112. Kong L, Wei J, Haider A, Liebelt B, Ling X, Conrad C, et al. Therapeutic targets in subependymoma. J Neuroimmunol. 2014;277:168-75 pubmed publisher
  113. Cousens L, Najafian N, Martin W, De Groot A. Tregitope: Immunomodulation powerhouse. Hum Immunol. 2014;75:1139-46 pubmed publisher
  114. Rueda C, Wells C, Gisslen T, Jobe A, Kallapur S, Chougnet C. Effect of chorioamnionitis on regulatory T cells in moderate/late preterm neonates. Hum Immunol. 2015;76:65-73 pubmed publisher
  115. Huss D, Mehta D, Sharma A, You X, Riester K, Sheridan J, et al. In vivo maintenance of human regulatory T cells during CD25 blockade. J Immunol. 2015;194:84-92 pubmed
  116. Willmann K, Klaver S, DoÄŸu F, Santos Valente E, Garncarz W, Bilic I, et al. Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity. Nat Commun. 2014;5:5360 pubmed publisher
  117. Dominguez Villar M, Gautron A, de Marcken M, Keller M, Hafler D. TLR7 induces anergy in human CD4(+) T cells. Nat Immunol. 2015;16:118-28 pubmed publisher
  118. Thauland T, Koguchi Y, Dustin M, Parker D. CD28-CD80 interactions control regulatory T cell motility and immunological synapse formation. J Immunol. 2014;193:5894-903 pubmed publisher
  119. Freeman A, Bridge J, Maruthayanar P, Overgaard N, Jung J, Simpson F, et al. Comparative immune phenotypic analysis of cutaneous Squamous Cell Carcinoma and Intraepidermal Carcinoma in immune-competent individuals: proportional representation of CD8+ T-cells but not FoxP3+ Regulatory T-cells is associated with disease stage. PLoS ONE. 2014;9:e110928 pubmed publisher
  120. Weed D, Vella J, Reis I, De La Fuente A, Gomez C, Sargi Z, et al. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2015;21:39-48 pubmed publisher
  121. Bacher P, Kniemeyer O, Teutschbein J, Thön M, Vödisch M, Wartenberg D, et al. Identification of immunogenic antigens from Aspergillus fumigatus by direct multiparameter characterization of specific conventional and regulatory CD4+ T cells. J Immunol. 2014;193:3332-43 pubmed publisher
  122. Jin J, Zhang W, Wong K, Kwak M, van Driel I, Yu Q. Inhibition of breast cancer resistance protein (ABCG2) in human myeloid dendritic cells induces potent tolerogenic functions during LPS stimulation. PLoS ONE. 2014;9:e104753 pubmed publisher
  123. Bending D, Pesenacker A, Ursu S, Wu Q, Lom H, Thirugnanabalan B, et al. Hypomethylation at the regulatory T cell-specific demethylated region in CD25hi T cells is decoupled from FOXP3 expression at the inflamed site in childhood arthritis. J Immunol. 2014;193:2699-708 pubmed publisher
  124. Skogberg G, Lundberg V, Lindgren S, Gudmundsdottir J, Sandström K, Kämpe O, et al. Altered expression of autoimmune regulator in infant down syndrome thymus, a possible contributor to an autoimmune phenotype. J Immunol. 2014;193:2187-95 pubmed publisher
  125. Noyan F, Lee Y, Zimmermann K, Hardtke Wolenski M, Taubert R, Warnecke G, et al. Isolation of human antigen-specific regulatory T cells with high suppressive function. Eur J Immunol. 2014;44:2592-602 pubmed publisher
  126. Kim K, Chung B, Kim B, Cho M, Yang C. The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients. Immunology. 2015;144:68-78 pubmed publisher
  127. Gupta M, Kolli D, Molteni C, Casola A, Garofalo R. Paramyxovirus infection regulates T cell responses by BDCA-1+ and BDCA-3+ myeloid dendritic cells. PLoS ONE. 2014;9:e99227 pubmed publisher
  128. Jitschin R, Braun M, Büttner M, Dettmer Wilde K, Bricks J, Berger J, et al. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood. 2014;124:750-60 pubmed publisher
  129. Hodi F, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014;2:632-42 pubmed publisher
  130. Gautron A, Dominguez Villar M, de Marcken M, Hafler D. Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells. Eur J Immunol. 2014;44:2703-2711 pubmed publisher
  131. Luciano A, Arbona Ramirez I, Ruiz R, Llorens Bonilla B, Martinez Lopez D, Funderburg N, et al. Alterations in regulatory T cell subpopulations seen in preterm infants. PLoS ONE. 2014;9:e95867 pubmed publisher
  132. Grage Griebenow E, Jerg E, Gorys A, Wicklein D, Wesch D, Freitag Wolf S, et al. L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression. Mol Oncol. 2014;8:982-97 pubmed publisher
  133. Kuwahara M, Suzuki J, Tofukuji S, Yamada T, Kanoh M, Matsumoto A, et al. The Menin-Bach2 axis is critical for regulating CD4 T-cell senescence and cytokine homeostasis. Nat Commun. 2014;5:3555 pubmed publisher
  134. Ito S, Bollard C, Carlsten M, Melenhorst J, Biancotto A, Wang E, et al. Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers. Mol Ther. 2014;22:1388-1395 pubmed publisher
  135. Keswani T, Bhattacharyya A. Differential role of T regulatory and Th17 in Swiss mice infected with Plasmodium berghei ANKA and Plasmodium yoelii. Exp Parasitol. 2014;141:82-92 pubmed publisher
  136. Berney Meyer L, Hung N, Slatter T, Schollum J, Kitching A, Walker R. Omeprazole-induced acute interstitial nephritis: a possible Th1-Th17-mediated injury?. Nephrology (Carlton). 2014;19:359-65 pubmed publisher
  137. Peguillet I, Milder M, Louis D, Vincent Salomon A, Dorval T, Piperno Neumann S, et al. High numbers of differentiated effector CD4 T cells are found in patients with cancer and correlate with clinical response after neoadjuvant therapy of breast cancer. Cancer Res. 2014;74:2204-16 pubmed publisher
  138. Naviglio S, Arrigo S, Martelossi S, Villanacci V, Tommasini A, Loganes C, et al. Severe inflammatory bowel disease associated with congenital alteration of transforming growth factor beta signaling. J Crohns Colitis. 2014;8:770-4 pubmed publisher
  139. Park S, Veerapu N, Shin E, Biancotto A, McCoy J, Capone S, et al. Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection. Nat Med. 2013;19:1638-42 pubmed publisher
  140. Shaw J, Hunt P, Critchfield J, McConnell D, Garcia J, Pollard R, et al. Short communication: HIV+ viremic slow progressors maintain low regulatory T cell numbers in rectal mucosa but exhibit high T cell activation. AIDS Res Hum Retroviruses. 2013;29:172-7 pubmed publisher
  141. Wolff M, Leung J, Davenport M, Poles M, Cho I, Loke P. TH17, TH22 and Treg cells are enriched in the healthy human cecum. PLoS ONE. 2012;7:e41373 pubmed publisher
  142. Nicholson I, Mavrangelos C, Bird D, Bresatz Atkins S, Eastaff Leung N, Grose R, et al. PI16 is expressed by a subset of human memory Treg with enhanced migration to CCL17 and CCL20. Cell Immunol. 2012;275:12-8 pubmed publisher
  143. Koreth J, Matsuoka K, Kim H, McDonough S, Bindra B, Alyea E, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365:2055-66 pubmed publisher
  144. Shaw J, Hunt P, Critchfield J, McConnell D, Garcia J, Pollard R, et al. Increased frequency of regulatory T cells accompanies increased immune activation in rectal mucosae of HIV-positive noncontrollers. J Virol. 2011;85:11422-34 pubmed publisher
  145. Caramori G, Lasagna L, Casalini A, Adcock I, Casolari P, Contoli M, et al. Immune response to Mycobacterium tuberculosis infection in the parietal pleura of patients with tuberculous pleurisy. PLoS ONE. 2011;6:e22637 pubmed publisher
  146. Ruffell B, Au A, Rugo H, Esserman L, Hwang E, Coussens L. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A. 2012;109:2796-801 pubmed publisher
  147. Wu Y, Ren M, Yang R, Liang X, Ma Y, Tang Y, et al. Reduced immunomodulation potential of bone marrow-derived mesenchymal stem cells induced CCR4+CCR6+ Th/Treg cell subset imbalance in ankylosing spondylitis. Arthritis Res Ther. 2011;13:R29 pubmed publisher
  148. Antonelli L, Mahnke Y, Hodge J, Porter B, Barber D, DerSimonian R, et al. Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome. Blood. 2010;116:3818-27 pubmed publisher
  149. French J, Weber Z, Fretwell D, Said S, Klopper J, Haugen B. Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2325-33 pubmed publisher
  150. Markley J, Sadelain M. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood. 2010;115:3508-19 pubmed publisher
  151. Oo Y, Weston C, Lalor P, Curbishley S, Withers D, Reynolds G, et al. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J Immunol. 2010;184:2886-98 pubmed publisher
  152. Hunter P, Nistala K, Jina N, Eddaoudi A, Thomson W, Hubank M, et al. Biologic predictors of extension of oligoarticular juvenile idiopathic arthritis as determined from synovial fluid cellular composition and gene expression. Arthritis Rheum. 2010;62:896-907 pubmed publisher
  153. Amarnath S, Costanzo C, Mariotti J, Ullman J, Telford W, Kapoor V, et al. Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. PLoS Biol. 2010;8:e1000302 pubmed publisher
  154. Antiga E, Quaglino P, Bellandi S, Volpi W, Del Bianco E, Comessatti A, et al. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br J Dermatol. 2010;162:1056-63 pubmed publisher
  155. Houot R, Goldstein M, Kohrt H, Myklebust J, Alizadeh A, Lin J, et al. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood. 2009;114:3431-8 pubmed publisher
  156. Ellestad K, Tsutsui S, Noorbakhsh F, Warren K, Yong V, Pittman Q, et al. Early life exposure to lipopolysaccharide suppresses experimental autoimmune encephalomyelitis by promoting tolerogenic dendritic cells and regulatory T cells. J Immunol. 2009;183:298-309 pubmed publisher
  157. Sivasankar B, Longhi M, Gallagher K, Betts G, Morgan B, Godkin A, et al. CD59 blockade enhances antigen-specific CD4+ T cell responses in humans: a new target for cancer immunotherapy?. J Immunol. 2009;182:5203-7 pubmed publisher
  158. Fujimaki W, Takahashi N, Ohnuma K, Nagatsu M, Kurosawa H, Yoshida S, et al. Comparative study of regulatory T cell function of human CD25CD4 T cells from thymocytes, cord blood, and adult peripheral blood. Clin Dev Immunol. 2008;2008:305859 pubmed publisher
  159. Koenen H, Smeets R, Vink P, van Rijssen E, Boots A, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood. 2008;112:2340-52 pubmed publisher
  160. Ebert L, Tan B, Browning J, Svobodova S, Russell S, Kirkpatrick N, et al. The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res. 2008;68:3001-9 pubmed publisher
  161. Pereira L, Villinger F, Wulff H, Sankaranarayanan A, Raman G, Ansari A. Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques. Exp Biol Med (Maywood). 2007;232:1338-54 pubmed
  162. Kang S, Lim H, Andrisani O, Broxmeyer H, Kim C. Vitamin A metabolites induce gut-homing FoxP3+ regulatory T cells. J Immunol. 2007;179:3724-33 pubmed
  163. Yates J, Rovis F, Mitchell P, Afzali B, Tsang J, Garin M, et al. The maintenance of human CD4+ CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. Int Immunol. 2007;19:785-99 pubmed
  164. Zuber J, Viguier M, Lemaitre F, Senée V, Patey N, Elain G, et al. Severe FOXP3+ and naïve T lymphopenia in a non-IPEX form of autoimmune enteropathy combined with an immunodeficiency. Gastroenterology. 2007;132:1694-704 pubmed
  165. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007;110:1225-32 pubmed
  166. Yu Q, Saruta M, Avanesyan A, Fleshner P, Banham A, Papadakis K. Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis. Inflamm Bowel Dis. 2007;13:191-9 pubmed
  167. Lim H, Broxmeyer H, Kim C. Regulation of trafficking receptor expression in human forkhead box P3+ regulatory T cells. J Immunol. 2006;177:840-51 pubmed